Fgr - FGR proto-oncogene, Src family tyrosine kinase Gene

Mus musculus

Also known as Ali18; Mhdaali18

Gene ID: 14191 | Gene type: protein coding

About Fgr

Summary

Enables several functions, including immunoglobulin receptor binding activity; non-membrane spanning protein tyrosine kinase activity; and phosphotyrosine residue binding activity. Involved in several processes, including defense response to Gram-positive bacterium; integrin-mediated signaling pathway; and regulation of vesicle-mediated transport. Acts upstream of or within bone mineralization and skeletal system morphogenesis. Located in plasma membrane. Colocalizes with actin Cytoskeleton and ruffle membrane. Is expressed in 2-cell stage embryo; blastocyst; nervous system; and neural ectoderm. Orthologous to human FGR (FGR proto-oncogene, Src family tyrosine kinase). [provided by Alliance of Genome Resources, Apr 2022]

Fgr Products(1)

mRNA	Protein	Name
NM_010208.4	NP_034338.3	tyrosine-protein kinase Fgr

Gene Ontology

Molecular Function
Biological Process
Cellular Component

Molecular Function GO Annotation	Evidence	Reference	Source
enables immunoglobulin receptor binding	IDA IDA: Inferred from direct assay	21746961	MGI
enables non-membrane spanning protein tyrosine kinase activity	IDA IDA: Inferred from direct assay	15561106	MGI
enables phosphotyrosine residue binding	IDA IDA: Inferred from direct assay	11672534	MGI
enables protein binding	IPI IPI: Inferred from physical interaction	16439675	MGI
enables protein kinase binding	IDA IDA: Inferred from direct assay	11672534	MGI
enables protein kinase binding	IPI IPI: Inferred from physical interaction	11672534	MGI

Biological Process GO Annotation	Evidence	Reference	Source
acts upstream of or within bone mineralization	IMP IMP: Inferred from mutant phenotype	16964445	MGI
acts upstream of or within defense response to Gram-positive bacterium	IGI IGI: Inferred from genetic interaction	8125254	MGI
involved in defense response to Gram-positive bacterium	IMP IMP: Inferred from mutant phenotype	8125254	MGI
involved in integrin-mediated signaling pathway	IMP IMP: Inferred from mutant phenotype	11672534	MGI
involved in negative regulation of natural killer cell activation	IMP IMP: Inferred from mutant phenotype	16439675	MGI
involved in peptidyl-tyrosine phosphorylation	IDA IDA: Inferred from direct assay	15561106	MGI
involved in positive regulation of cell migration	IMP IMP: Inferred from mutant phenotype	15561106	MGI
involved in positive regulation of cytokine production	IDA IDA: Inferred from direct assay	21746961	MGI
involved in positive regulation of mast cell degranulation	IDA IDA: Inferred from direct assay	21746961	MGI
involved in regulation of cell shape	IMP IMP: Inferred from mutant phenotype	11672534	MGI
involved in regulation of innate immune response	IMP IMP: Inferred from mutant phenotype	21746961	MGI
involved in regulation of phagocytosis	IMP IMP: Inferred from mutant phenotype	11672534	MGI
involved in regulation of protein kinase activity	IDA IDA: Inferred from direct assay	11672534	MGI
acts upstream of or within skeletal system morphogenesis	IMP IMP: Inferred from mutant phenotype	16964445	MGI

Cellular Component GO Annotation	Evidence	Reference	Source
colocalizes with actin cytoskeleton	IDA IDA: Inferred from direct assay	15561106	MGI
located in plasma membrane	IDA IDA: Inferred from direct assay	15561106	MGI
colocalizes with ruffle membrane	IDA IDA: Inferred from direct assay	15561106	MGI

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Protein Preferred Names

Protein Names

tyrosine-protein kinase Fgr

Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog	p55-Fgr
proto-oncogene c-Fgr	proto-oncogene tyrosine-protein kinase Fgr

Related Agents

Approval

Bioactive Molecules (1)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-10230	Midostaurin		99.91%	Yes

Clinical Phase

Bioactive Molecules (5)

Cat. No.	Product Name	Effect	Purity	Phase
HY-10234	Saracatinib		99.92%	Phase 3
HY-10234A	Saracatinib difumarate	Inhibitor	99.24%	Phase 3
HY-15322	PRT062607	Inhibitor	99.38%	Phase 2
HY-10186	TG 100801	Inhibitor	98.61%	Phase 2
HY-10187	TG 100801 Hydrochloride	Inhibitor	/	Phase 2

Pre-clinical Phase

Bioactive Molecules (10)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-15141	Staurosporine		99.98%	Unkown
HY-112852	TL02-59		99.84%	Unkown
HY-10185	TG 100572 Hydrochloride	Inhibitor	98.96%	Unkown
HY-10230S	Midostaurin-d5	Inhibitor	≥98.0%	Unkown
HY-10184	TG 100572	Inhibitor	/	Unkown
HY-112852A	TL02-59 dihydrochloride		/	Unkown
HY-145373	BMS-986143	Inhibitor	/	Unkown
HY-RS04929	FGR Human Pre-designed siRNA Set A	Pre-designed Sets	/	Unkown
HY-RS19562	Fgr Mouse Pre-designed siRNA Set A	Pre-designed Sets	/	Unkown
HY-RS26058	Fgr Rat Pre-designed siRNA Set A	Pre-designed Sets	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Fgr	NCBI	NCBI:2268

Name
Email *

	Sorry, but the email address you supplied was invalid.